Objective To study the clinical safety of Yanxiping Injection

Reduning Injection and Tanreqing Injection in extensive population. Methods A prospective

multicentral

and large sample post-market safety monitoring was conducted. Totally 10029 hospitalized patients with infectious diseases used the above 3 TCM injections were centrally monitored from September 2012 to October 2013. The clinical features and suspected drugs in patients with adverse reactions（ ADRs） were recorded in detail. Results The incidence of ADRs was 0. 26%（ 26 / 10029）. All ADRs were first reported. There were 24 cases of general ADRs

one case of severe ADR and one case of new-onset ADR. Most of the patients with ADRs aged under 9

mainly infants and children

mainly with respiratory diseases as the primary disease

occurred in 0. 5 h after treatment and with main symptoms of abdominal pain

diarrhea and fever common. There were 6 patients used other injections before this study and 20 patients used other injections after this study. Conclusion Yanxiping Injection

Reduning Injection and Tanreqing Injection are safe in extensive population with a lower incidence of ADR. The occurrence of the ADRs may be relevant to medication standard and combined medication.